SVRA

Company Overview — What Does Savara Inc Do?

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas. Savara Inc (SVRA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Matthew Pauls and employs approximately 20 people, headquartered in Wilmington, Texas. With a market capitalization of $1.1B, SVRA is one of the notable companies in the Healthcare sector.

Savara Inc (SVRA) Stock Rating — Hold (April 2026)

As of April 2026, Savara Inc receives a Hold rating with a composite score of 38.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.SVRA ranks #1,595 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Savara Inc ranks #141 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SVRA Stock Price and 52-Week Range

Savara Inc (SVRA) currently trades at $5.66. The stock lost $0.21 (3.6%) in the most recent trading session. The 52-week high for SVRA is $7.00, which means the stock is currently trading -19.2% from its annual peak. The 52-week low is $1.89, putting the stock 199.5% above its annual trough. Recent trading volume was 1.8M shares, reflecting moderate market activity.

Is SVRA Overvalued or Undervalued? — Valuation Analysis

Savara Inc (SVRA) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.54x, versus the sector average of 2.75x.

At current multiples, Savara Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Savara Inc Profitability — ROE, Margins, and Quality Score

Savara Inc (SVRA) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -78.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -43.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SVRA Debt, Balance Sheet, and Financial Health

Savara Inc has a debt-to-equity ratio of 32.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.85x, indicating strong short-term liquidity. Total debt on the balance sheet is $30M. Cash and equivalents stand at $16M.

SVRA has a beta of 0.82, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Savara Inc is 44/100, reflecting average volatility within the normal range for its sector.

Savara Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Savara Inc reported revenue of $0 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-111M. Operating income came in at $-116M.

In FY 2025, Savara Inc reported revenue of $0 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-119M. Operating income came in at $-124M.

In Q3 2025, Savara Inc reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-30M. Operating income came in at $-30M.

In Q2 2025, Savara Inc reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-30M. Operating income came in at $-31M.

Over the past 8 quarters, Savara Inc has experienced revenue contraction from $0 to $0. Investors analyzing SVRA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SVRA Dividend Yield and Income Analysis

Savara Inc (SVRA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SVRA Momentum and Technical Analysis Profile

Savara Inc (SVRA) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

SVRA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Savara Inc (SVRA) ranks #141 out of 838 stocks based on the Blank Capital composite score. This places SVRA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SVRA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SVRA vs S&P 500 (SPY) comparison to assess how Savara Inc stacks up against the broader market across all factor dimensions.

SVRA Next Earnings Date

No upcoming earnings date has been announced for Savara Inc (SVRA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SVRA? — Investment Thesis Summary

Savara Inc presents a balanced picture with arguments on both sides. The quality score of 18/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers.

In summary, Savara Inc (SVRA) earns a Hold rating with a composite score of 38.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SVRA stock.

Related Resources for SVRA Investors

Explore more research and tools: SVRA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SVRA head-to-head with peers: SVRA vs AZN, SVRA vs SLGL, SVRA vs VMD.